scholarly journals Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center

2018 ◽  
Vol 2 (4) ◽  
pp. 304-312 ◽  
Author(s):  
Michael E. Lidsky ◽  
William R. Jarnagin
2005 ◽  
Vol 241 (5) ◽  
pp. 693-702 ◽  
Author(s):  
Alan W. Hemming ◽  
Alan I. Reed ◽  
Shiro Fujita ◽  
David P. Foley ◽  
Richard J. Howard

2021 ◽  
Author(s):  
Dauren Adilbay ◽  
Cristina Valero ◽  
Conall Fitzgerald ◽  
Avery Yuan ◽  
Ximena Mimica ◽  
...  

2017 ◽  
Vol 6 (3) ◽  
pp. 588-598
Author(s):  
Xi-Yu Liu ◽  
Zong-Chao Gou ◽  
Zhi-Gang Cao ◽  
Yi-Zhou Jiang ◽  
Zhi-Ming Shao

2007 ◽  
Vol 177 (4) ◽  
pp. 1330-1334 ◽  
Author(s):  
Philippe E. Spiess ◽  
Wassim Kassouf ◽  
Gordon A. Brown ◽  
Ashish M. Kamat ◽  
Ping Liu ◽  
...  

2020 ◽  
Vol 2020 (3) ◽  
Author(s):  
David Fan ◽  
Stephanie Luster ◽  
Ibrahim G Eid ◽  
Abdul Saied Calvino

Abstract Carotid body tumors (CBTs) are rare and usually require complex surgical resection. We present a case of a large 7-cm CBT successfully treated in a community cancer center using a multidisciplinary team approach. A 32-year-old male referred for surgical evaluation of an asymptomatic right neck mass. CT angiography showed a 7-cm tumor encasing the carotid vessels, including the bifurcation (Shamblin III). Preoperative angiography and embolization were performed by interventional radiology. The patient underwent surgical removal of the CBTs and required surgical reconstruction with a common carotid to internal carotid bypass using a polytetrafluoroethylene interposition graft. The hypoglossal nerve, vagus nerve and glossopharyngeal nerve were identified, meticulously dissected and preserved. The patient did well after surgery and recovered with no complications. This report examines the diagnosis, preoperative workup and surgical management of CBTs using a multidisciplinary team approach.


2008 ◽  
Vol 15 (8) ◽  
pp. 2113-2119 ◽  
Author(s):  
Liu Yubin ◽  
Fang Chihua ◽  
Jian Zhixiang ◽  
Ou Jinrui ◽  
Liu Zixian ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e18033-e18033
Author(s):  
Trish Dinh ◽  
Natalie Andrews Wright ◽  
Hari Iyer ◽  
Johanne I Weberpals

e18033 Background: Recurrent VSCC carries a poor prognosis, but real-world data on outcomes with standard treatment options are lacking. Specifically, progression free survival (PFS) in recurrent VSCC is ill-defined which is problematic for the design of clinical trials with novel therapies. We aim to address the paucity of outcome data in recurrent VSCC and to compare PFS and overall survival (OS) in patients (pts) undergoing surgery, chemotherapy, radiotherapy or a combination of these treatments. Methods: A retrospective chart review identified 246 pts from 2000-2018 diagnosed with VSCC treated at the Ottawa Hospital Cancer Center and 61 pts with recurrent disease. Data collected included patient demographics, tumour characteristics, recurrence pattern, and treatment modality (surgery only, surgery with chemotherapy, surgery with radiation, surgery with chemoradiation, chemoradiation only, chemotherapy only, or radiation only). Descriptive statistical analysis is reported. Results: Among all study pts, the stage distribution was stage I: 28%, II: 19%, III: 43% and IV: 10%. 61% of pts had one recurrence, 36% had two recurrences, and 3% had three recurrences. The 5-year survival rate was 78% for non-recurrent VSCC vs. 33% for recurrent cases. The median OS for all recurrent and non-recurrent cases was 3.7 years and 13.5 years, respectively. For primary treatment, 87% underwent surgical treatment, of which 60% also had radiation or chemoradiation. The most common treatments for first recurrence were: surgery (25%), radiation (20%), no treatment (16%) and chemotherapy (14%), and for second recurrence: no treatment (50%), radiation (25%), surgery (17%) and chemotherapy (8%). The median PFS after primary treatment and after first and second recurrences were 8.7, 5.3 and 1.4 months (mo), respectively, with no significant difference between treatment regimens. However, when grouped (surgery with or without chemotherapy, radiation or chemoradiation vs. non-surgical management), there was a significant PFS benefit for surgical (15.6 mo) over non-surgical management (0.7 mo) in the treatment of a second recurrence (p = 0.05). Conclusions: At our centre, surgery and radiation have been the mainstay of treatment for recurrent VSCC with particular advantage of surgery in the treatment of a second recurrence. Our study establishes a baseline for VSCC outcomes following standard treatment. Accurate PFS data is an important outcome for the design of future studies in recurrent VSCC with new drug therapies.


2017 ◽  
Vol 6 (6) ◽  
pp. 1351-1357
Author(s):  
Yuchen Wu ◽  
Fangqi Liu ◽  
Guoxiang Cai ◽  
Minghe Wang ◽  
Hongtu Zheng ◽  
...  

2007 ◽  
Vol 15 (3) ◽  
pp. 754-763 ◽  
Author(s):  
Niraj J. Gusani ◽  
Sung W. Cho ◽  
Christos Colovos ◽  
Songwon Seo ◽  
Jan Franko ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document